Koichi Azuma
YOU?
Author Swipe
View article: Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab
Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab Open
Our results suggest that PFS and OS are negatively affected by elevated CXCL9, CXCL10, and CCL23 levels after CCRT followed by durvalumab treatment. These soluble mediators may be useful tools for the clinical management of locally advance…
View article: Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 <scp>ADRIATIC</scp> Trial
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 <span>ADRIATIC</span> Trial Open
At the first interim analysis of the global, randomized, phase 3, double‐blind ADRIATIC trial in patients with limited‐stage small‐cell lung cancer (LS‐SCLC) not progressing after concurrent chemoradiotherapy (cCRT), consolidation durvalum…
View article: Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment
Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment Open
Background and Aim Long‐term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long‐term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients wit…
View article: Supplementary Data S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Supplementary Data S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Supplementary Data S1. Study Protocol of JCOG1404/WJGO8214L.
View article: Figure 1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Figure 1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
CONSORT diagram. Flowchart of patient disposition throughout the study, including randomization, eligibility, treatment, and follow-up.
View article: Table 3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Table 3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Safety summary.
View article: Supplementary Figure S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Supplementary Figure S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Supplementary Figure S1. Study hypothesis. Abbreviations: EGFR; epidermal growth factor receptor; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor.
View article: Supplementary Table S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Supplementary Table S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Supplementary Table S1. Representativeness of study participants.
View article: Table 1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Table 1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Patient characteristics. Data are presented as median (range) or n (%).
View article: Supplementary Figure S2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Supplementary Figure S2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Supplementary Figure S2. Study design of JCOG1404/WJOG8214L. Abbreviations: NSCLC, non-small cell lung cancer; EGFR; epidermal growth factor receptor; Exon 19 DEL, EGFR exon 19 deletion; Exon 21 L858R, EGFR exon 21 L858 point mutation; ECO…
View article: Table 2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Table 2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Subsequent treatment.
View article: Figure 3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Figure 3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Kaplan–Meier analysis of PFS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 49.2%, 26.0%, 18.0%, 12.9%, and 7.8% in the control group and 67.0%, 39.8%, 24.1%, 11.9%, and 9.5% in the experimental group, respectively. B, G…
View article: Supplementary Figure S4 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Supplementary Figure S4 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Supplementary Figure S4. Subgroup analyses of progression-free survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, E…
View article: Supplementary Figure S3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Supplementary Figure S3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Supplementary Figure S3. Subgroup analyses of overall survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon …
View article: Data from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Data from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Purpose:This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first-…
View article: Figure 2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Figure 2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Kaplan–Meier analysis of OS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year survival rates were 92.8%, 80.4%, 63.5%, 49.6%, and 36.9% in the control group and 94.4%, 81.7%, 69.9%, 49.9%, and 35.3% in the experimental group, respectively…
View article: Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring <i>EGFR</i> Mutation Open
Purpose: This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first…
View article: Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset Open
Amivantamab-lazertinib demonstrated superior progression-free survival versus osimertinib in Asian participants, with a tolerable safety profile. These results were consistent with those in the overall population.
View article: Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals
Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals Open
Background and Aim More accurate stratification of patients with chronic hepatitis C after permanent hepatitis C virus (HCV) clearance by direct‐acting antivirals (DAAs) is important for improving long‐term surveillance and treatment. The …
View article: Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study)
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study) Open
This is the prospective study to evaluate the efficacy of immunochemotherapy in patients with advanced or relapsed LCNEC. The results are expected to contribute to establishing the treatment strategy for LCNEC.
View article: Evaluation of Corrosion Potential Stability of Stainless Steels in Dilute Electrolyte Solution for Application to a Quasi-Reference Electrode Used in Electrochemical Sensing System
Evaluation of Corrosion Potential Stability of Stainless Steels in Dilute Electrolyte Solution for Application to a Quasi-Reference Electrode Used in Electrochemical Sensing System Open
To evaluate the long term corrosion potential stability of stainless steel (SS) in environmental water, the corrosion potential of SUS304, SUS316, SUS316L, and SUS430 was measured for 1 week in a solution of 0.9 mM NaHCO3 and 0.5 mM CaCl2,…